Crystalline and amorphous forms of a β-arrestin effector
AssigneeTrevena, Inc.
InventorsRitesh Sanghvi, Gregory Alcorn, Graham Richard Lawton, Meiki Yu, Matthew Ronsheim, Jiaher Tian, Shao Hong Zhou, Yuriy B. Kalyan
Life of this patent
Estimating the term…
Abstract
The present disclosure provides novel crystalline forms of a compound that acts as a β-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a β-arrestin effector and uses thereof.
Claims25
A crystalline form of a polypeptide having the amino acid sequence SEQ.ID.NO.1, wherein the form is Form I of SEQ.ID.NO.1.
A process for preparing a crystalline form of a polypeptide having an amino acid sequence of SEQ.ID.NO.1, comprising crystallizing SEQ.ID.NO.1 to form Form I of SEQ.ID.NO.1 and optionally isolating the Form I of SEQ.ID.NO.1.
A method of treating a cardiovascular or a cardiorenal disorder comprising administering to a patient in need thereof a crystalline Form I of a polypeptide having an amino acid sequence of SEQ.ID.NO.1.
Dependencies are inferred from the claim text.